Trump’s Drug Czar (White Freemason) Pick Exposed For Being on Big Pharma’s Payroll

News For The Blind
By Annabelle Bamforth

President Donald Trump’s reported choice to serve as Director of the Office of National Drug Control Policy has raised alarm concerning conflict of interest, as his top pick has been criticized for protecting and benefiting from the pharmaceutical industry.

The ONDCP is responsible for most of the shaping of U.S. drug policy and will also be “providing administrative support” for Trump’s newly-created special commission to combat the opiate crisis. Trump’s top choice, Pennsylvania Congressman Tom Marino, is expected to resign from Congress to become the country’s “drug czar.”

For those who seek to genuinely hold the pharmaceutical industry accountable for its role in the country’s opiate crisis, Marino is a perilous choice. The International Business Times has uncovered troubling background of Marino’s relationship with the pharmaceutical industry, particularly regarding donations.

According to IBT, Marino “would come to the job after pulling in big money from an industry that is producing and distributing the nation’s most…

View original post 527 more words


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s